WEBINAR
Cancers display widespread RNA dysregulation, including alternative splicing of transcripts. These aberrant transcripts are often translated into cancer-specific proteins and have been shown to affect cancer initiation, progression, metastasis, and drug resistance. While it has been recently reported that cancer-specific isoforms can be used as novel prognostic biomarkers and serve as an untapped source of drug targets for immuno-oncology, the vast majority of cancer specific isoforms remain unknown. With at least 95% of genes undergoing alternative splicing and producing multiple isoforms, much remains to be discovered.
Join us for this webinar to learn:
"Quotation here"
Author, Affiliation
Register for webinar
Associate Professor
The Jackson Laboratory
Associate Director, Cancer Research
PacBio
Ted Kalbfleisch, Ph.D., Associate Professor, University of Kentucky
Mitchell Feldmann, Ph.D., Postdoctoral Fellow, University of California, Davis.